Background: Diazepam is one of the most widely prescribed tranquilizers for the therapy of alcohol withdrawal syndrome (AWS), which includes the symptoms of anxiety, fear, and emotional tension. However, diazepam therapy often turns out to be ineffective, and some patients experience dose-dependent adverse drug reactions, reducing the efficacy of therapy. Aim: The purpose of our study was to investigate the effects of CYP2C19*17 genetic polymorphisms on the steady-state concentration of diazepam in patients with AWS. Materials and Methods: The study was conducted on 50 Russian male patients suffering from the AWS. For the therapy of psychomotor agitation, anxiety, fear, and emotional tension, patients received diazepam in injections at a dosage of 30.0 mg/day for 5 days. Genotyping was performed by real-time polymerase chain reaction. The efficacy and safety assessment was performed using psychometric scales and scales for assessing the severity of adverse drug reactions. Therapeutic drug monitoring (TDM) was performed using the high-performance liquid chromatography-mass spectrometry (HPLC-MS/MS) method. Results: Based on the results of the study, we revealed the differences in the efficacy of therapy in patients with different CYP2C19 −806C>T genotypes: (*1/*1) −12.0 [−15.0; −8.0], (*1/*17+*17/*17) −7.0 [−14.0; −5.0], P < .001, as well as the results of TDM: (CC) 250.70 [213.34; 308.53] ng/mL (*1/*17+*17/*17) 89.12 [53.26; 178.07] ng/mL, P < .001. Conclusion: Thus, our study enrolling 50 patients with AWS, showed the effects of CYP2C19*17 genetic polymorphisms on the efficacy and safety rates of diazepam. Furthermore, we revealed the statistically significant difference in the levels of plasma steady-state concentrations of diazepam in patients carrying different genotypes.
FukasawaTSuzukiAOtaniK.Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines. J Clin Pharm Ther. 2007;32(4):333-341.
BenedictNJWongACassidyE, et al. Predictors of resistant alcohol withdrawal (RAW): a retrospective case-control study. Drug Alcohol Depend. 2018;192:303-308.
4.
HackJBHoffmanRSNelsonLS.Resistant alcohol withdrawal: does an unexpectedly large sedative requirement identify these patients early?J Med Toxicol. 2006;2(2):55-60.
5.
SarffMGoldJA.Alcohol withdrawal syndromes in the intensive care unit. Crit Care Med. 2010;38(Suppl 9):S494-S501.
6.
GoldJARimalBNolanANelsonLS.A strategy of escalating doses of benzodiazepines and phenobarbital administration reduces the need for mechanical ventilation in delirium tremens. Crit Care Med. 2007;35(3):724-730.
7.
GriffinCEIIIKayeAMBuenoFRKayeAD.Benzodiazepine pharmacology and central nervous system-mediated effects. Ochsner J. 2013;13(2):214-223.
8.
SchmitzA.Benzodiazepine use, misuse, and abuse: a review. Ment Health Clin. 2016;6(3):120-126. doi:10.9740/mhc.2016.05.120.
9.
SkryabinVYZastrozhinMSTorradoMV, et al. How do CYP2C19*2 and CYP2C19*17 genetic polymorphisms affect the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome?Drug Metab Pers Ther. 2020;35(1). doi:10.1515/dmpt-2019-0026.
10.
FukasawaTYasui-FurukoriNSuzukiAInoueYTateishiTOtaniK.Pharmacokinetics and pharmacodynamics of etizolam are influenced by polymorphic CYP2C19 activity. Eur J Clin Pharmacol. 2005;61(11):791-795.
11.
ZastrozhinMSSkryabinVYMiroshkinSSBryunEASychevDA.Pharmacogenetics of alcohol addiction: current perspectives. Appl Clin Genet. 2019;12:131-140. doi:10.2147/TACG.S206745.
12.
DeanL. Diazepam therapy and CYP2C19 genotype In: PrattVMcLeodHRubinsteinWDeanLKattmanBMalheiroA, eds. Medical Genetics Summaries. Bethesda, MD: National Center for Biotechnology Information (US); 2012-2016.
13.
KranzlerHREdenbergHJ.Pharmacogenetics of alcohol and alcohol dependence treatment. Curr Pharm Des. 2010;16(19): 2141-2148.
14.
DeshpandeNSharanyaVRavi KanthVV, et al. Rapid and ultra-rapid metabolizers with CYP2C19*17 polymorphism do not respond to standard therapy with proton pump inhibitors. Meta Gene. 2016;9:159-164. doi:10.1016/j.mgene.2016.06.004.
15.
ZastrozhinMSSavchenkoLMBryunEA, et al. Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder. Pharmacogenomics Pers Med2018;11:113-119. doi:10.2147/PGPM.S160763.
16.
ZastrozhinMSGrishinaERyzhikovaKA, et al. The influence of CYP3A5 polymorphisms on haloperidol treatment in patients with alcohol addiction. Pharmgenomics Pers Med. 2018;11:1-5.
17.
NussMAElnickiDMDunsworthTSMakelaEH.Utilizing CIWA-Ar to assess use of benzodiazepines in patients vulnerable to alcohol withdrawal syndrome. W V Med J. 2004;100(1):21-25.
18.
LingjaerdeOAhlforsUGBechPDenckerSJElgenK.The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1-100.
19.
Food and Drug Administration. Draft Guidance for Industry: Bioanalytical Method Validation. Rockville, MD: U.S. Food and Drug Administration; 1999.
20.
MelnikEVPetukhovAEKozinSVPomerantsevaTYRamenskayaGV.Validated HPLC-MS/MS method for quantification of ethylmethylhydroxypyridine succinate in rat brain and its application to a pharmacokinetic study. J Chromatogr B: Analyt Technol Biomed Life Sci. 2018;1096:180-186. doi:10.1016/j.jchromb.2018.08.029.
